Ocrelizumab Reduces Thalamic Volume Loss, – Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences
Using the phase 3 OPERA I and II and ORATORIO studies, investigators found significantly reduced thalamic volume loss in patients with relapsing (RMS) and primary progressive multiple sclerosis (PPMS) treated with ocrelizumab (Ocrevus; Genentech) compared with those on interferon beta-1a or placebo. Led by Douglas Arnold, MD, neurologist, Montreal Neurological Institute and Hospital, and Department of Neurology and Neurosurgery, McGill University, the study showed that ocrelizumab had the greatest effect on thalamic volume compared with whole brain, and white or cortical gray matter. “This could be explained from the perspective that thalamic injury may reflect much of the MS-related damage that occurs throughout the whole CNS and may not be specific to the thalamus only,” Arnold et al wrote. Thalamic loss, typically occurring early in patients with MS, has been associated with loss in disability progression, measured by changes in Expanded Disability Status Scale (EDSS) and cognitive impairment.
CLICK HERE to watch a video about this topic
Click to Subscribe for the MS Beacon eNewsletter and MS educational events
|
